A blood test developed by Alamar Biosciences can stage the progression of Alzheimer’s disease in the brain, researchers reported in Boston at the Clinical Trials on Alzheimer’s Disease conference, in a study published in JAMA.
The test measures eMTBR-tau, a biomarker that reflects the degree of accumulation of tau protein tangles in brain cells. Existing blood tests for Alzheimer’s measure proteins such as beta-amyloid and phosphorylated tau, whose levels rise in the early stages of the disease, but which provide limited information on the accumulation of tau tangles at more advanced stages.
Two Alzheimer’s drugs currently on the market are designed to reduce beta-amyloid plaques in the brain, but several drugs targeting tau protein are in development. A test that can stage tau accumulation matters for both treatment decisions and trial enrollment.
“One of the major challenges in diagnosing Alzheimer’s disease is establishing, in a patient with cognitive impairment, not only that the pathology is present, but also that it is at a sufficiently advanced biological stage to plausibly explain the symptoms,” said Dr. Niklas Mattsson-Carlgren of Lund University in Sweden, who led the study.
Blood test helps tau tangle detection
- A simple blood draw may eventually help doctors determine the extent of tau tangle accumulation in the brain.
- The test is not yet available for clinical use and is not intended to diagnose Alzheimer’s disease on its own, the researchers stated in the study report.
- Combined with existing blood tests, it could help doctors make better therapeutic decisions and identify patients suitable for clinical trials.
Test measures tau tangle buildup
Current blood tests detect proteins such as beta-amyloid and phosphorylated tau. The eMTBR-tau test measures the degree of accumulation of tau protein tangles in brain cells to help determine the stage of Alzheimer’s disease.
“Having a simple but highly scalable way to determine the extent of tau tangle accumulation in the brain represents a major advance in our understanding of Alzheimer’s disease,” said Nicholas Ashton, co-leader of the study at the Banner Sun Health Research Institute in Sun City, Arizona, according to Boursorama.
| Biomarker | What it reflects | Clinical status |
|---|---|---|
| Beta-amyloid | Plaque buildup | Available in existing tests |
| Phosphorylated tau | Rises early; limited insight into later tangle burden | Available in existing blood tests |
| eMTBR-tau | Degree of accumulation of tau tangles in brain cells | Research only; published in JAMA |
What remains unproven
The test is not yet available for clinical purposes and is not intended to diagnose Alzheimer’s disease on its own, as stated by the researchers in the study report.
Aging brains lose their overnight self-cleaning rhythm
Experiments in awake subjects offered partial explanations. In many older subjects, neuronal activity increased, but blood flow did not increase much, suggesting that the ability of blood vessels to respond to increased oxygen demand has decreased.
A breath-holding test produced a smaller average increase in blood flow in older participants than in younger subjects. Together, these two factors explained much, but not all, of the decrease in CSF flow, the researchers indicated.
When to Consult a Doctor
The eMTBR-tau test is not yet available for clinical purposes. No blood test is intended to diagnose Alzheimer’s disease on its own. Anyone with concerning memory changes or cognitive symptoms should consult a physician for a full clinical evaluation.
References
- Study report on the eMTBR-tau test, published in JAMA (study led by Dr. Niklas Mattsson-Carlgren, Lund University; co-led by Nicholas Ashton, Banner Sun Health Research Institute); presented at the Clinical Trials on Alzheimer’s Disease conference, Boston.
- Sleep and cerebrospinal-fluid flow study, published in Nature Aging (study led by Laura Lewis, MIT, Cambridge, Massachusetts).